Microsomal cytochromes P450 catalyze the oxidation of low density lipoprotein

Atherosclerosis

Volumn 143, Issue 2, 1999, Pages 253-260

  Aviram, Michael ^a   Kent, Ute M ^b   Hollenberg, Paul F ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cytochrome P450; LDL; Lipid peroxidation; Superoxide

Indexed keywords

CATALASE; CYTOCHROME P450; HYDROGEN PEROXIDE; LOW DENSITY LIPOPROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ARTERY WALL; ARTICLE; ATHEROGENESIS; ENZYME ACTIVITY; HUMAN; LIPID PEROXIDATION; LIPID STORAGE; LIVER MICROSOME METABOLISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 0032895114     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00296-2     Document Type: Article

References (42)

1. Aviram M. Oxidized low density lipoprotein (Ox-LDL) interaction with macrophages in atherosclerosis and the antiatherogenicity of antioxidants. Eur. J. Clin. Chem. Biochem. 34:1996;599-608.
2. Berliner J.A., Navab M., Fogelman A.M., Frank J.L.S., Demer L.L., Edwards P.A. Atherosclerosis: basic mechanisms oxidation, inflammation and genetics. Circulation. 91:1995;2488-2498.
3. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:1989;915-924.
4. Yla-Herttuala S., Palinski W., Rosenfeld M.E., Pharthasarathy S., Carew T.E., Buttler S., Witztum J.L., Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84:1989;1086-1095.
5. Aviram M., Rosenblat M. Macrophage-mediated oxidation of extracellular low density lipoprotein requires an initial binding of the lipoprotein to its receptor. J. Lipid Res. 35:1994;385-398.
6. Heinecke J.W. Mechanisms of oxidative damage of low density lipoprotein in human atherosclerosis. Curr. Opin. Lipidol. 8:1997;268-274.
7. Parthasarathy S., Weiland E., Steinberg D. A role for endothelial cell lipoxygenase in the oxidative modification of LDL. Proc. Natl. Acad. Sci. (USA). 86:1989;1046-1050.
8. Aviram M., Rosenblat M., Etzioni A., Levy R. Activation of NADPH oxidase but not of 15-lipoxygenase by low density lipoprotein (LDL) in the presence of copper ions is required for LDL oxidation by macrophages. Metabolism. 45(9):1996;1069-1079.
9. 2 and phospholipase D are involved in macrophage NADPH oxidase-mediated oxidation of LDL. Isr. J. Med. Sci. 32:1996;749-756.
10. Cathcart M.K., McNally A.K., Morel D.W. Superoxide anion participation in human monocyte-mediated oxidation of LDL and conversion of LDL to a cytotoxin. J. Immunol. 142:1989;1963-1972.
11. Rosenblat M., Aviram M. Macrophage glutathione content and glutathione peroxidase activity are inversely related to cell-mediated oxidation of LDL. Free Radic. Biol. Med. 24:1998;305-317.
12. Fuhrman B., Oiknine J., Aviram M. Iron induces lipid peroxidation in cultured macrophages increases their ability to oxidatively modify LDL and affects their secretory properties. Atherosclerosis. 111:1994;65-78.
13. Keidar S., Kaplan M., Hoffman A., Brook J.G., Aviram M. Angiotensin II stimulates macrophage-mediated lipid peroxidation of low density lipoprotein. Atherosclerosis. 115:1995;201-215.
14. Fuhrman B., Oiknine J., Keidar S., Kaplan M., Aviram M. Increased uptake of low density lipoprotein (LDL) by oxidized macrophages is the result of enhanced LDL receptor activity and of progressive LDL oxidation. Free Radic. Biol. Med. 23:1997;34-46.
15. Nelson D.R., Koymans L., Kamataki T., Stegeman J.J., Feyereisen R., Waxman D.J., Waterman M.R., Gothoh O., Coon M.J., Estabrook R., Gunsalus I.C., Nebert D.W. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 6:1996;1-42.
16. Gergel B., Misok V., Riesz P., Cederbaum A.I. Inhibition of rat and human cytochrome P4502E1 catalytic activity and reactive oxygen radical formation by nitric oxide. Arch. Biochem. Biophys. 337:1997;239-250.
17. Lambert N., Chambers S.J., Plumb G.W., Williamson G. Human cytochrome P450's are pro-oxidants in iron/ascorbate-initiated microsomal lipid peroxidation. Free Radic. Res. 24:1996;177-185.
18. Dushkin M.I., Zenkov N.K., Menshikova E.B., Pivovarova E.N., Liubimov G., Volskii N.N. Ketoconazole inhibits oxidative modification of LDL. Atherosclerosis. 114:1995;9-18.
19. Oinonen T., Lindros K.O. Zonation of hepatic cytochrome P450 expression and regulation. Biochem. J. 329:1998;17-35.
20. Ronis M.J.J., Lindros K.O., Ingelman-Sundberg M. The CYP2E subfamily. Iomides C. Cytochrome P450: Metabolic and Toxicological Aspects. 1996;211-239 CRC Press, Boca Raton, FL.
21. Larson J.R., Coon M.J., Porter T.D. Alcohol-inducible cytochrome P450IIE1 lacking the hydrophobic NH2-terminal segment retains catalytic activity and is membrane-bound when expressed in Escherichia coli. J. Biol. Chem. 266:1991;7321-7324.
22. Saito T., Strobel H.W. Purification to homogeneity and characterization of a form of cytochrome P450 with high specificity for benzopyrene from beta-naphthoflavone pretreated rat liver microsomes. J. Biol. Chem. 256:1981;984-988.
23. Gillam E.M., Baba T., Kim B.R., Ohmori S., Guengerich F.P. Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch. Biochem. Biophys. 305:1993;123-131.
24. Hanna I.H., Teiber J.F., Kokones K.L., Hollenberg P.F. Role of alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH- and hydroperoxide-supported activities. Arch. Biochem. Biophys. 350:1998;324-332.
25. He K., Iyer K.R., Hayes R.N., Sinz M.W., Woolf T.F., Hollenberg P.F. Inactivation of cytochrome P450 2A4 by bergamottin, a component of grapefruit juice. Chem. Res. Toxicol. 11:1998;252-259.
26. Aviram M. Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients. Biochem. Med. 30:1983;111-118.
27. Buege J.A., Aust S.D. Microsomal lipid peroxidation. Methods Enzymol. 52:1978;302-310.
28. El-Saadani M., Esterbauer H., El-Sayed M., Goher M., Nassar A.Y., Jurgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J. Lipid Res. 30:1989;627-630.
29. Esterbauer H., Striegl G., Puhl H., Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic. Res. Commun. 6:1989;67-75.
30. Aviram M. Modified forms of LDL and atherosclerosis. Atherosclerosis. 98:1993;1-9.
31. Bond J.A., Yang H.Y., Majesky M.W., Benditt E.P., Juchau M.R. Metabolism of benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene in chicken aortas:monooxygenation, biocactivation to mutagens, and covalent binding to DNA in vitro. Toxicol. Appl. Pharmacol. 52:1980;323-335.
32. Bond J.A., Kocan R.M., Benditt E.P., Juchau M.R. Metabolism of benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene in cultured human fetal aortic smooth muscle cells. Life Sci. 25:1979;425-430.
33. Majesky M.W., Yang H.-Y.L., Benditt E.P., Juchau M.R. Carcinogenesis and atherogenesis: differences in monooxygenase inducibility and bioactivation of benzo[a]pyrene in aortic and hepatic tissues of atherosclerotic-susceptible versus resistant pigeons. Carcinogenesis. 4:1983;647-652.
34. Rendic S., DiCarlo F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29:1997;413-580.
35. 3 and molecular modeling of the oxidase form. J. Biol. Chem. 268:1993;2953-2959.
36. Pagano P.J., Clark J.K., Cifuentes-Pagano E., Clark S.M., Callis G.M., Quinn M.T. Localization of a constitutively active phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc. Natl. Acad. Sci. (USA). 94:1997;14483-14488.
37. Reiss A.B., Martin K.O., Roger D.E., Iyer S., Grossi E.A., Galloway A.C., Javitt N.B. Sterol 27-hydroxylase: experssion in human arterial endothelium. J. Lipid Res. 38:1997;1254-1260.
38. Babiker A., Andersson O., Lund E., Xiu R.J., Deeb S., Reshef A., Leitersdorf E., Diczfalusy U., Bjorkhem I. Elimination of cholestrol in macrophages and endothelial cells by the sterol 27-hydroxylase mechanism. J. Biol. Chem. 272:1997;26253-26261.
39. Irizar A., Ioannides C. Experssion and inducibility of cytochrome P450 proteins belonging to families 2, 3, and 4 in the rabbit aorta. Biochem. Biophys. Res. Commun. 213:1995;916-921.
40. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J. Clin. Invest. 101:1998;1581-1590.
41. Aviram M., Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, Dunlop C, La Du B. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different than that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 1998;18:1617-24.
42. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson RC, Bisgaier CL, Newton RS, La Du BN. Oxidized lipids in oxidized LDL inactivate human serum paraoxonase (PON 1): role for PON1 free sulfhydryl group. Free Radic Biol Med 1999; in press.